NCT01047891View on ClinicalTrials.gov

Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

174

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Ovarian Cancer

Interventions

DRUG

Sorafenib

Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered

Trial Locations (1)

13355

Charité Campus Virchow-Klinikum, Berlin